The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease

Cardiology (Switzerland)

Volumn 126, Issue 4, 2013, Pages 224-229

  Sung, Ki Won ^a   Jeon, Yang Bin ^a   Kim, Na Yeon ^b   Park, Kook Yang ^a   Park, Chul Hyun ^a   Choi, Chang Hyu ^a   Choi, Deok Young ^a  

^a Gachon University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Congenital heart disease; Iloprost; Pulmonary arterial hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ILOPROST; NITRIC OXIDE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHEST TUBE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HEART FUNCTION; HEART SURGERY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; NAUSEA AND VOMITING; OXYGEN SATURATION; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEART SEPTAL DEFECTS, ATRIAL; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFANT; PERIOPERATIVE CARE; RETROSPECTIVE STUDIES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84888274044     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000354248     Document Type: Article

References (27)

1. Tulloh RM: Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005; 6: 174-180.
2. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L: Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15: 816-822, discussion 822-823.
3. Lee JE, Hillier SC, Knoderer CA: Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008; 23: 329-334.
4. Baker SE, Hockman RH: Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39: 1265-1274.
5. Dimopoulos K, Peset A, Gatzoulis MA: Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008; 129: 163-171.
6. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH: Shortand long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169.
7. Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, Höffken G, Anker SD, Negassa A, Felix SB, Hetzer R, Ewert R: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895-1902.
8. Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, Antoniou T: Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 2002; 49: 963-967.
9. Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, Zuk J, Piepenbrock S, Strüber M: Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008; 22: 406-413.
10. Hoeper MM, Barber JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M: Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54(suppl 1):S85-S96.
11. Beghetti M, Galiè N: Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 733-740.
12. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M: Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, doubleblind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
13. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
14. Tissot C, Beghetti M: Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009; 5: 325-331.
15. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004; 102: 139-153.
16. Goldsmith DR, Wagstaff AJ: Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004; 64: 763-773, discussion 774-775.
17. Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, Lang IM: Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 2009; 137: 760-761.
18. Kim YH, Yu JJ, Yun TJ, Lee Y, Kim YB, Choi HS, Jhang WK, Shin HJ, Park JJ, Seo DM, Ko JK, Park IS: Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg 2010; 89: 1629-1630.
19. Lopes AA, OLeary PW: Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009; 19: 431-435.
20. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension - German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
21. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544-548.
22. Milo-Cotter O, Cotter-Davison B, Lombardi C, Sun H, Bettari L, Bugatti S, Rund M, Metra M, Kaluski E, Kobrin I, Frey A, Rainisio M, McMurray JJ, Teerlink JR, Cotter-Davison G: Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 2011; 119: 96-105.
23. Knirsch W, Husermann E, Fasnacht M, Hersberger M, Gessler P, Bauersfeld U: Plasma B-type natriuretic peptide levels in children with heart disease. Acta Paediatr 2011; 100: 1213-1216.
24. Yang D, Liu Z, Yang Z: Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology 2013; 124: 241-245.
25. Rastogi D, Ngai P, Barst RJ, Koumbourlis AC: Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children. Pediatr Pulmonol 2004; 37: 50-55.
26. Winterhalter M, Antoniou T, Loukanov T: Management of adult patients with perioperative pulmonary hypertension: technical aspects and therapeutic options. Cardiology 2010; 116: 3-9.
27. Gorenflo M: Perioperative care in patients with pulmonary hypertension after cardiac surgery: clinical management, outcome and future clinical research - results from an expert meeting. Cardiology 2010; 116: 1-2.